A logo for Pfizer is displayed on a monitor on the floor at the New York Stock Exchange, July 29, 2019.
Brendan McDermid | Reuters
Pfizer reported a 9% drop in fourth-quarter revenue, hurt by intense competition for its pain treatment Lyrica that lost patent protection last year.
Revenue at the company, which is set to spin off its off-patent branded drugs business and combine it with generic drugmaker Mylan, fell to $12.69 billion from $13.98 billion a year earlier.
Net loss attributable to Pfizer narrowed to $337 million, or 6 cents per share, in the quarter, from $394 million, or 7 cents per share, a year earlier.